Group 1 - SNDL Inc. has completed the acquisition of 5 cannabis retail stores located in Alberta and Saskatchewan from 1CM Inc. [1] - This transaction marks the first closing under the amended and restated arrangement agreement dated December 15, 2025, with a second closing anticipated in the first half of 2026 for 27 additional stores in Ontario, pending regulatory approvals [2] - SNDL is one of the largest vertically integrated cannabis companies in Canada and the largest private-sector liquor and cannabis retailer, with various retail banners and consumer-facing cannabis brands [3] Group 2 - 1CM Inc. operates as a retailer of cannabis and liquor in Canada, focusing on developing cash-flow positive locations and pursuing growth through organic development and mergers and acquisitions [4]

Group 1 - Pomerantz LLP is investigating claims on behalf of investors of SNDL Inc. regarding potential securities fraud or unlawful business practices by the company and its officers/directors [1] - On December 15, 2025, SNDL announced an amendment to its agreement to acquire 32 cannabis retail stores from 1CM, maintaining a total purchase price of $32.2 million in cash, but splitting the acquisition into two closings for regulatory approval [2] - Following the announcement of the amended acquisition agreement, SNDL's stock price fell by $0.29 per share, or 13.12%, closing at $1.92 per share on December 15, 2025 [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving SNDL Inc. and its officers or directors [1] Group 1: Company Developments - On December 15, 2025, SNDL announced an amendment to its agreement to acquire 32 cannabis retail stores from 1CM Inc., maintaining a total purchase price of $32.2 million in cash, but splitting the acquisition into two closings for regulatory approval [3] - Following the announcement of the amended agreement, SNDL's stock price decreased by $0.29 per share, or 13.12%, closing at $1.92 per share on the same day [3]

Core Viewpoint - President Donald Trump's executive order marks a significant shift in federal cannabis policy, directing federal agencies to loosen regulations on marijuana [1] Regulatory Changes - The order instructs U.S. Attorney General Pam Bondi to expedite the rescheduling of marijuana to Schedule III under the Controlled Substances Act, aligning it with common painkillers but not fully legalizing it [2] - Marijuana's current classification as a Schedule I substance has limited research opportunities, and reclassification aims to enhance studies on safety and effectiveness, particularly for vulnerable populations [4] Access to CBD Products - The order outlines steps to improve access to hemp-derived cannabinoid products, especially cannabidiol (CBD), which currently lacks a clear regulatory pathway through the FDA [5] - It directs the White House Deputy Chief of Staff to collaborate with Congress to expand access to full-spectrum CBD products while restricting those posing health risks [6] Political Reactions - Senate Minority Leader Chuck Schumer supports the order, viewing it as a positive step, but emphasizes the need for further decriminalization and easing banking regulations for the cannabis industry [7] - Conversely, some Republican senators, including Ted Budd, criticize the order as shortsighted and potentially harmful to youth [7][8] Market Reactions - Cannabis stocks initially surged following the announcement but retreated by the close, attributed to the lack of expected cannabis banking provisions in the order [9] - Despite the retreat, major cannabis stocks have seen significant gains throughout the month in anticipation of the executive order [11]

Core Viewpoint - SNDL shares experienced a nearly 12% increase following reports of a potential reclassification of cannabis as a "Schedule III" drug by the Trump administration, which may also allow seniors access to cannabis products under Medicare coverage [1][2]. Company Developments - SNDL stock has shown volatility, currently down over 25% from its year-to-date high in early October despite recent gains [2]. - The company has agreed to acquire 32 cannabis retail stores from 1CM in Canada, which could enhance its market share as it expands its retail footprint in key provinces like Ontario, Alberta, and Saskatchewan [3][4]. - SNDL reported a record $16.7 million in free cash flow for Q3, positioning the company well for growth initiatives in the upcoming year [4]. Market Position and Valuation - SNDL shares are currently trading at a price-sales multiple of less than 1x, indicating an inexpensive valuation relative to the long-term potential of the cannabis industry [5]. - The recent rally has pushed SNDL shares above $2, reducing the delisting risk that had previously affected the stock [5]. - Options traders anticipate a more than 20% increase in SNDL shares by January 16, suggesting a potential trading price of $2.53 in early 2026 [6]. Analyst Outlook - Wall Street analysts project that SNDL stock could more than double in value over the next year, driven by favorable policy changes [7].

Core Points - SNDL Inc. and 1CM Inc. have entered into an amended and restated arrangement agreement to acquire 32 cannabis retail stores for a total purchase price of $32.2 million in cash [1][3] Group 1: Transaction Details - The transaction will be completed in two stages: the first closing will involve 5 stores in Alberta and Saskatchewan, while the second closing will involve 27 stores in Ontario [2] - The purchase price for the first closing is set at $5.0 million, and for the second closing at $27.2 million, with the total purchase price remaining unchanged [3] - The deadline for completing the transaction has been extended from December 31, 2025, to May 31, 2026 [2] Group 2: Shareholder and Court Approvals - 1CM's shareholders voted overwhelmingly in favor of the transaction, and a final court order was obtained on June 18, 2025 [4] - A court hearing is scheduled for January 5, 2026, to seek approval for the amendments to the transaction [4] Group 3: Financial Implications - 1CM plans to return a portion of the net proceeds from the transaction to its shareholders after the second closing [5] - The net proceeds from the first closing are expected to cover transaction costs and working capital [5] Group 4: Company Backgrounds - SNDL Inc. is one of the largest vertically integrated cannabis companies in Canada, with a diverse portfolio of retail brands and products [6] - 1CM Inc. operates cannabis and liquor retail locations and aims to continue expanding through organic growth and future mergers and acquisitions [7]

Core Viewpoint - Cannabis stocks experienced a significant surge, with Tilray Brands (TLRY.US) rising over 32%, Canopy Growth (CGC.US) increasing over 23%, SNDL (SNDL.US) up over 19%, Aurora Cannabis (ACB.US) gaining over 11%, and Cronos Group (CRON.US) climbing over 5% due to reports that President Donald Trump is considering reclassifying cannabis to a lower harm category [1] Group 1 - Tilray Brands (TLRY.US) saw an increase of over 32% [1] - Canopy Growth (CGC.US) rose by more than 23% [1] - SNDL (SNDL.US) experienced a gain of over 19% [1] Group 2 - Aurora Cannabis (ACB.US) increased by more than 11% [1] - Cronos Group (CRON.US) rose by over 5% [1] - Reports indicate that Trump is considering moving cannabis from Schedule I to Schedule III, indicating a potential shift in regulatory stance [1]

Core Viewpoint - The stock prices of major cannabis companies surged significantly following reports of President Trump's plans to relax federal regulations on marijuana, with notable increases in premarket trading [1][2]. Group 1: Stock Price Movements - Tilray Brands (NASDAQ:TLRY) saw a price increase of 34.88%, while Canopy Growth (NASDAQ:CGC) rose by 27.46% in premarket trading [1]. - Other companies also experienced substantial gains: Aurora Cannabis Inc. (NASDAQ:ACB) surged 20%, Cronos Group Inc. (NASDAQ:CRON) gained 19%, Organigram Global Inc. (NASDAQ:OGI) rose 12%, and SNDL Inc. (NASDAQ:SNDL) increased by 34.7% [1]. Group 2: Regulatory Changes - The surge in stock prices was attributed to news that Trump plans to instruct federal agencies to reclassify marijuana as a Schedule III drug, which would change its regulatory status [2][3]. - This reclassification would subject cannabis companies to different tax regulations, potentially attracting more investments and placing marijuana in the same category as substances like steroids and Tylenol with codeine [3]. Group 3: Historical Context - Trump had previously hinted at this reclassification in August, indicating a consistent approach towards cannabis regulation [3]. - The anticipated change is expected to occur early next year, moving marijuana from a category that includes heroin to a lower tier for less dangerous substances [4].

Core Viewpoint - The potential reclassification of cannabis by President Trump from Schedule I to Schedule III is expected to significantly benefit the cannabis industry, leading to a surge in stock prices for major cannabis producers in the U.S. [1][2] Group 1: Market Reaction - Major cannabis producers saw substantial stock price increases in pre-market trading, with Tilray Brands (TLRY.US) rising over 30%, Canopy Growth (CGC.US) up 23%, Aurora Cannabis (ACB.US) increasing by 20%, SNDL (SNDL.US) gaining 14%, and Cronos Group (CRON.US) up 12% [1] - The market response indicates strong investor optimism regarding the potential regulatory changes surrounding cannabis [1] Group 2: Regulatory Context - President Trump is considering moving cannabis from Schedule I, which indicates no medical use and high abuse potential, to Schedule III, which includes substances with accepted medical uses but some potential for abuse [1][2] - Schedule III drugs include substances like ketamine and anabolic steroids, while Schedule I includes LSD and heroin [2] - The Biden administration previously proposed a similar reclassification in March 2024, but the DEA canceled related hearings [2] Group 3: Political and Industry Implications - Trump's discussions with key officials and cannabis industry executives suggest a serious consideration of the reclassification, which could alleviate criminal penalties for personal use and remove certain federal tax and business barriers [2] - The reclassification could improve the operating environment for legal cannabis businesses and their employees [2] - Robert F. Kennedy Jr., nominated by Trump for the Department of Health and Human Services, has advocated for ending cannabis criminalization and implementing a regulated sales system [3]

Core Viewpoint - Four cannabis stocks are showing significant technical momentum despite new regulatory challenges from Washington, particularly a provision in a government funding bill that could re-criminalize many hemp-derived THC products [1][2]. Group 1: Stock Performance - The stocks demonstrating gains include Tilray Brands Inc. (NASDAQ:TLRY), Cronos Group Inc. (NASDAQ:CRON), Organigram Global Inc. (NASDAQ:OGI), and SNDL Inc. (NASDAQ:SNDL) [2]. - Benzinga Edge's Stock Rankings indicate that all four companies exhibit strong positive momentum, particularly over the last six months [3]. - The six-month returns for the stocks are as follows: TLRY at 156.82%, CRON at 20.39%, OGI at 26.23%, and SNDL at 32.81% [4]. Group 2: Individual Stock Analysis - TLRY shows a weaker price trend in the short term but strong trends in medium and long terms, with a pre-market decline of 1.77% [6]. - CRON maintains a weaker short-term price trend but strong medium and long-term trends, with a pre-market increase of 3.63% [6]. - OGI has a weaker price trend in the short and medium terms but a strong long-term trend, with a pre-market decline of 1.95% [6]. - SNDL has a moderate growth ranking despite weaker trends across all timeframes, with a pre-market increase of 2.35% [6]. Group 3: Regulatory Environment - A new legislative provision in the funding package re-criminalizes intoxicating hemp products, which could significantly impact the market [7]. - Senator Rand Paul criticized the provision, stating it could eliminate nearly 100% of legal hemp products overnight, adversely affecting farmers [7]. - The regulatory changes may benefit multi-state operators by reducing "gray-market" competition but are expected to negatively impact Canadian companies like Tilray, which viewed the hemp-derived product segment as a key entry point into the U.S. market [8].